# Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy

> **NCT00378014** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 276 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** everolimus
- **DRUG:** basiliximab
- **DRUG:** CNI

## Key facts

- **NCT ID:** NCT00378014
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2015-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378014, "Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00378014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*